SCHEMBL714008

SCHEMBL714008

CC(C)(C)[SiH2]OC(C)(C)[C@H]1CN(c2ccc(OCC3(OP(=O)(OCc4ccccc4)OCc4ccccc4)CCN(c4cc5c(cc4F)c(=O)c(C(=O)OCc4ccccc4)cn5C4CC4)CC3)c(F)c2)C(=O)O1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
LMNA P02545 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
MAPT P10636 1/20 0.37
TOP2B Q02880 3/20 0.36
PIK3CG P48736 2/20 0.35
PIK3CD O00329 1/20 0.34
PIK3R1 P27986 1/20 0.34
PIK3CA P42336 1/20 0.34
CYP1A2 P05177 1/20 0.34
TOP2A P11388 1/20 0.34
CYP2C9 P11712 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712052 0.91 KDM4E (0.39) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL714007 0.88 TOP2B (0.39) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL584341 0.84
SCHEMBL712447 0.83 TOP2B (0.42) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL712446 0.83 TOP2B (0.42) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL12342302 0.82 TOP2B (0.47) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL2108803 0.82 TOP2B (0.47) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL712051 0.79 TOP2B (0.41) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL541887 0.79 TOP2B (0.43) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL711428 0.79 TOP2B (0.43) KDM4EALDH1A1LMNAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124623-B2 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials ACTELION PHARMACEUTICALS LTD. (CH) 2012-02-28 US disclosed
US-20090247578-A1 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS ACTELION PHARMACEUTICALS LTD. (CH) 2009-10-01 US disclosed
EP-2086968-A1 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-08-12 EP disclosed
WO-2008056335-A1 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247578-A1 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS OGFOD1, OXGR1, ODC1 KDM4E 1365/4885ALDH1A1 1227/4885LMNA 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.